IP Library › Granted Patent US 7,482,377
Granted Patent B2
US 7,482,377 · App. 11/132,024 · Granted Jan 27, 2009

Pharmaceutical compositions and methods of treatment based on diclofenac

Assignee: Kowa Pharmaceuticals America, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,482,377
App. No.
11/132,024
Granted
Jan 27, 2009
Kind
B2
Abstract

New pharmaceutical compositions for oral use containing diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other, side effects; in particular, these formulations permit to obtain in human patients higher C max of the active principle and shorter T max together with a lower coefficient of variation.

Claims (15)

1. A method of treating pain comprising administering to a host in need thereof a pharmaceutical formulation for oral administration containing diclofenac in its acid and/or salt form together with one or more alkali metal bicarbonates and customary excipients and adjuvants, wherein said alkali metal bicarbonates are present in an amount of from 20 to 80% by weight based on the weight of the acid form of diclofenac, and further wherein said formulation when administered is an intact tablet, or a powder formulation dissolved or dispersed in water, and wherein said formulation contains not more than 50 mg of diclofenac potassium or the equivalent amount of diclofenac or an alternative pharmaceutically acceptable diclofenac salt.

2. The method of claim 1 wherein said diclofenac is present in its potassium and/or sodium salt form.

3. The method of claim 2 wherein said formulation is administered as an intact tablet.

4. The method of claim 2 wherein said formulation is administered as a powder formulation dissolved or dispersed in water.

5. The method of claim 2 wherein said alkali metal bicarbonates are potassium and/or sodium bicarbonates.

6. The method of claim 1 wherein said formulation is administered as an intact tablet.

7. The method of claim 1 wherein said formulation is administered as a powder formulation dissolved or dispersed in water.

8. The method of claim 1 further comprising, before administering said formulation, providing a unit dose powder of diclofenac in acid and/or salt form and dissolving or dispersing said diclofenac in water to provide said formulation.

9. The method of claim 1 wherein said formulation is a liquid.

10. The method of claim 1 wherein said formulation comprises diclofenac potassium and potassium bicarbonate.

11. A method of treating pain comprising administering to a host in need thereof a pharmaceutical formulation for oral administration containing diclofenac as 50 mg. of diclofenac potassium together with one or more alkali metal bicarbonates or carbonates or mixtures thereof and customary excipients and adjuvants, wherein said alkali metal bicarbonates or carbonates or mixtures thereof are present in an amount of from 20 to 80% by weight based on the weight of the acid form of diclofenac, and further wherein said formulation when administered is an intact tablet or a powder formulation dissolved or dispersed in water.

12. The method of claim 11 wherein said formulation is a tablet comprising 50 mg. of diclofenac potassium.

13. The method of claim 11 further comprising, before administering said formulation, providing a unit dose powder of diclofenac potassium and dissolving or dispersing said diclofenac potassium in water to provide said formulation.

14. The method of claim 11 wherein said formulation is a liquid.

15. A method of treating pain according to claim 1 , comprising orally administering to a host in need thereof a pharmaceutical formulation for oral administration containing diclofenac in sodium or potassium salt form together with sodium or potassium bicarbonates or mixtures thereof and customary excipients and adjuvants, wherein said sodium or potassium bicarbonates are present in an amount of from 20 to 80% by weight based on the weight of the acid form of diclofenac.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2009
From: KOWA PHARMACEUTICALS AMERICA, INC.
To: APR APPLIED PHARMA RESEARCH SA
Reel/Frame 023588/0620 →
CHANGE OF NAME Recorded Jan 22, 2009
From: PROETHIC PHARMACEUTICALS, INC.
To: KOWA PHARAMCEUTICALS AMERICA, INC.
Reel/Frame 022137/0158 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2006
From: APR APPLIED PHARMA RESEARCH SA
To: PROETHIC PHARMACEUTICALS, INC.
Reel/Frame 018425/0023 →
Priority Claims (1)
IT MI96A0992 · May 17, 1996 · national
Continuity (4)
Continuation 0952474700 · Mar 14, 2000
Continuation 0919249300 · Nov 17, 1998
Continuation PCTEP970270900 · May 15, 1997
Related Publication 20050214363A1 · Sep 29, 2005